Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Silence Therapeutics plc (NASDAQ:SLN), a biotechnology company specializing in RNA therapeutics, stands at a crucial juncture ...

Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...

Akribion Therapeutics ("Akribion"), the early-stage biotech developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Atalanta Therapeutics has technology that delivers RNA interference therapies into the CNS. The startup has spent the past four years quietly working on its technology and potential drugs.

German biotech Akribion Therapeutics has emerged from stealth with 8 million euros ($9 million) in seed funding to accelerate ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...

The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.